FTM
BECOME A MEMBER
() () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () ()

Tag Archives: Revive

  • Home
  •  | 
  • Tag Archives: "Revive"

Revive Therapeutics Announces FDA Grants Orphan Drug Designation for Cannabidiol in the Prevention of Ischemia and Reperfusion Injury from Organ Transplantation

Revive Therapeutics Announces FDA Grants Orphan Drug Designation for Cannabidiol in the Prevention of Ischemia and Reperfusion Injury from Organ Transplantation
Revive Therapeutics Ltd. (TSX VENTURE: RVV) (OTCQB: RVVTF) (FSE:31R) ("Revive" or the “Company”), a specialty cannabis company focused on the research, development and commercialization of novel cannabinoid-based products, today announced that the U.S. Food and Drug Administration (“FDA”) has granted orphan drug designation for cannabidiol (“CBD”) in the prevention of ischemia and reperfusion injury (“IRI”) resulting from solid organ transplantation.
Read more

Revive Therapeutics Introduces RELICANN™ a New Brand for Hemp-based CBD Wellness and Medical Cannabis Market

Revive Therapeutics Introduces RELICANN™ a New Brand for Hemp-based CBD Wellness and Medical Cannabis Market
Sept. 11, 2018 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (TSX VENTURE: RVV) (OTCQB: RVVTF) (FSE: 31R) (“Revive” or the “Company”), a specialty cannabis company focused on the research, development and commercialization of novel cannabinoid-based products, today announced the introduction of RELICANN™, the Company’s hemp-based  and medical cannabis brand designed for the health and wellness and medical cannabis consumer.  The Company’s first product under the RELICANN™ brand is RELICANN™ hemp-based Cannabidiol (“CBD”) gum, which will be available in Canada in the fourth-quarter of 2018.
Read more

Revive Therapeutics Provides Corporate Update

Revive Therapeutics Provides Corporate Update
Revive is focused on commercializing differentiated cannabis-based products that have patent protection and best-in-class with first mover advantage offering a better alternative over conventional cannabis-based products in the market.  The Company’s patent portfolio includes exclusive rights to five issued U.S. patents, one issued Canadian patent and two patent applications filed in the U.S., based on cannabinoid delivery systems and uses for specific diseases.  The Company’s first product to be launched in Canada is a proprietary, unique hemp-based cannabidiol (“CBD”) chewing gum, which Revive signed an exclusive distribution and license agreement with AXIM® Biotechnologies, Inc. to market the product throughout Canada.  The Company anticipates launching its hemp-based CBD chewing gum product under Revive’s brand in the fourth quarter of this year.
Read more